Ensign Peak Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.5M Sell
36,949
-3,430
-8% -$146K ﹤0.01% 755
2026
Q2
$1.64M Buy
+40,379
New +$1.39M ﹤0.01% 779
2025
Q1
– Sell
-80,509
Closed -$2.15M – 1698
2024
Q4
$2.15M Buy
+80,509
New +$2.56M ﹤0.01% 904
2022
Q2
– Sell
-662,526
Closed -$6.43M – 2178
2022
Q1
$6.43M Buy
+662,526
New +$8.53M 0.01% 522

Other funds holding EWTX

Ensign Peak Advisors's EWTX Position: Q3 2026 in Review

Ensign Peak Advisors reduced its Edgewise Therapeutics (EWTX) stake by 8.5% in Q3 2026, selling an estimated $146K and leaving 36,949 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Ensign Peak Advisors first reported a position in EWTX in Q1 2022 and has held it in 4 quarters since. The position peaked at $6.43M in Q1 2022. 253 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

  • Ensign Peak Advisors held 36,949 shares of Edgewise Therapeutics worth $1.5M as of Q3 2026.
  • Ensign Peak Advisors sold 3,430 Edgewise Therapeutics shares in Q3 2026, an estimated $146K.
  • Edgewise Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #755 holding.
  • Ensign Peak Advisors first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 4 quarters since.
  • Ensign Peak Advisors's Edgewise Therapeutics position peaked at $6.43M in Q1 2022.
  • 253 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.